An Orthogonal Nucleic Acid/Peptide Amplification Circuit Enables Protease‐Triggered, Cancer Cell‐Selective PD‐L1 Imaging
Angewandte Chemie International Edition · 2026
DOI: 10.1002/anie.202520284 ↗Kurz gefasst
Fachartikel in der Zeitschrift Angewandte Chemie International Edition, 2026. Verfasst von Bo Wu und 3 weiteren Autor:innen. Beteiligte Einrichtung: CAS Key Laboratory for Biomedical Effects of Nanomaterials and Nanosafety, National Center for Nanoscience and Technology, Beijing, 100190, China. Hauptthemen laut MEDLINE: B7-H1 Antigen, Peptide Hydrolases, Peptides, Neoplasms. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 53 Literaturangaben. Gefördert von: National Key R&D Program of China, National Natural Science Foundation of China, CAS Project for Young Scientists in Basic Research.
Abstract (Originalsprache)
Molecular imaging offers a powerful approach for in situ detection of programmed death‐ligand 1 (PD‐L1), however, achieving cancer cell‐selective imaging that discriminates PD‐L1 expression on malignant versus normal cells remains a challenge. Here, we present an orthogonal nucleic acid/peptide amplification circuit that integrates protease‐activated hybridization chain reaction (HCR) with aptamer‐mediated target recognition for cancer‐selective PD‐L1 imaging. In the design, PD‐L1 aptamer is coupled with an HCR initiator for targeting PD‐L1, while PNA is employed as a bridge scaffold to engineer the initiator with protease‐responsive peptide substrate and thus block the HCR. Within the tumor microenvironment, protease‐mediated peptide cleavage liberates the initiator, thereby triggering localized HCR amplification at PD‐L1 sites. In contrast, in normal tissues lacking the relevant proteases, the initiator remains inactive, yielding markedly improved spatial selectivity for cancer cell‐specific PD‐L1 imaging. Using mouse models, we further demonstrate that this strategy allows for non‐invasive assessment of tumor responses to immune checkpoint blockade therapy. This methodology will build a bridge between DNA nanobiotechnology and peptide‐based biochemistry for diverse biomedical applications.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- CAS Key Laboratory for Biomedical Effects of Nanomaterials and Nanosafety, National Center for Nanoscience and Technology, Beijing, 100190, China.
- College of Materials Science and Optoelectronic Technology, University of Chinese Academy of Sciences, Beijing, 100049, China.
ORCID-Profile: Lele Li
Förderung
- National Key R&D Program of China
- National Natural Science Foundation of China
- CAS Project for Young Scientists in Basic Research
- the Youth Innovation Promotion Association CAS
- National Key Research and Development Program of China
Zitieren
APA
Wu, B., Yi, X., Zhao, J., & Li, L. (2026). An Orthogonal Nucleic Acid/Peptide Amplification Circuit Enables Protease‐Triggered, Cancer Cell‐Selective PD‐L1 Imaging. Angewandte Chemie International Edition. https://doi.org/10.1002/anie.202520284
Vancouver
Wu B, Yi X, Zhao J, Li L. An Orthogonal Nucleic Acid/Peptide Amplification Circuit Enables Protease‐Triggered, Cancer Cell‐Selective PD‐L1 Imaging. Angewandte Chemie International Edition. 2026. doi:10.1002/anie.202520284
BibTeX
@article{Wu2026,
author = {Wu, Bo and Yi, Xiulin and Zhao, Jian and Li, Lele},
title = {An Orthogonal Nucleic Acid/Peptide Amplification Circuit Enables Protease‐Triggered, Cancer Cell‐Selective PD‐L1 Imaging},
journal = {Angewandte Chemie International Edition},
year = {2026},
doi = {10.1002/anie.202520284}
}
EUVIMED